TriangleAtezolizumab (NCT06069726)
Atezolizumab trial for Recurrent Glioblastoma (NCT06069726). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with IDH-wildtype glioblastoma at first or second recurrence after radiation and temozolomide, who can undergo tumor surgery. Previous immunotherapy excludes participation.
The idea: atezolizumab blocks PD-L1 to support immune attack. Patients receive one dose before surgery and continue afterward until progression or another stopping reason. Tumor sequencing separates low- and high-mutation-burden groups; both receive treatment. Researchers compare survival between groups and with matched historical patients to identify possible response markers.
This phase 2 study plans 80 patients. Mustafa Khasraw leads at Duke in Durham; three US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.